| pubmed-article:8443962 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8443962 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8443962 | lifeskim:mentions | umls-concept:C2243049 | lld:lifeskim |
| pubmed-article:8443962 | lifeskim:mentions | umls-concept:C0178468 | lld:lifeskim |
| pubmed-article:8443962 | lifeskim:mentions | umls-concept:C0376315 | lld:lifeskim |
| pubmed-article:8443962 | lifeskim:mentions | umls-concept:C0279694 | lld:lifeskim |
| pubmed-article:8443962 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8443962 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8443962 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:8443962 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8443962 | pubmed:dateCreated | 1993-4-5 | lld:pubmed |
| pubmed-article:8443962 | pubmed:abstractText | Anti-CD3 (OKT3) MoAb is a mitogenic agent which activates lymphocytes. We have studied the effects of murine anti-human OKT3 MoAb (IgG1) alone or in combination with IL-2, human thyroglobulin (Tg) and thyroperoxidase (TPO) antigens on the proliferation of whole peripheral blood mononuclear cells (PBMC) (including monocytes) or subtypes (T, CD4+, CD8+, B) as measured by tritiated thymidine (3H-TdR) incorporation. B cell differentiation was studied by measuring numbers of IgG-secreting cells and specific anti-TPO/anti-Tg-secreting cells by SPOT ELISA. PBMC or lymphocyte subtypes, obtained from 45 patients with Hashimoto's thyroiditis (HT), 40 Graves' disease (GD) and 51 normal controls were cultured in 96 microtitre plates for 6 days in the presence of OKT3 MoAb at final concentrations 25-250 ng/ml, IL-2 15 U/ml, Tg and TPO (1 micrograms/ml). Then cultures were pulsed with 0.2 microCi 3H-TdR/well and incorporation was measured after 18 h. IgG and anti-TPO/Tg-secreting cells were detected at 7 days. Higher proliferative responses from whole PBMC preparations in response to any of the combinations including OKT3 MoAb were observed in the HT preparations, while the basal values were the lowest. IL-2 alone increased these responses markedly, but equally in all groups. IL-2 in combination with OKT3 had an additive effect on proliferation, with higher responses in HT. Tg and TPO antigens did not change these responses. Most HT preparations responded with their maximum proliferation to the lowest concentration of OKT3 MoAb (25 ng/ml), whereas in GD and control preparations of PBMC these responses were shifted to higher concentrations (250 ng/ml); even with those, proliferation was not so enhanced in controls when compared with HT and GD preparations. In contrast, the proliferative responses of T cells alone and subpopulations of CD8+ suppressor/cytotoxic cells were decreased in HT preparations compared with controls. Monocytes were necessary for proliferation. In the subpopulation of B cells (> 95% pure) and CD4+ helper/inducer cells, differences did not reach significance. In spite of the effect on proliferation, OKT3 MoAb only mildly but significantly increased the numbers of IgG-secreting cells in HT and GD preparations and did not stimulate synthesis of specific antibodies. Our data suggest that the increased proliferative responses of whole PBMC to OKT3 MoAb in HT preparations might be due to insufficient activation of T suppressor/cytotoxic cells. | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8443962 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8443962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443962 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8443962 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8443962 | pubmed:issn | 0009-9104 | lld:pubmed |
| pubmed-article:8443962 | pubmed:author | pubmed-author:MoritzMM | lld:pubmed |
| pubmed-article:8443962 | pubmed:author | pubmed-author:CarayonPP | lld:pubmed |
| pubmed-article:8443962 | pubmed:author | pubmed-author:KimHH | lld:pubmed |
| pubmed-article:8443962 | pubmed:author | pubmed-author:VolpéRR | lld:pubmed |
| pubmed-article:8443962 | pubmed:author | pubmed-author:YoshikawaNN | lld:pubmed |
| pubmed-article:8443962 | pubmed:author | pubmed-author:ResetkovaEE | lld:pubmed |
| pubmed-article:8443962 | pubmed:author | pubmed-author:ArreazaGG | lld:pubmed |
| pubmed-article:8443962 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8443962 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:8443962 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8443962 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8443962 | pubmed:pagination | 397-403 | lld:pubmed |
| pubmed-article:8443962 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:meshHeading | pubmed-meshheading:8443962-... | lld:pubmed |
| pubmed-article:8443962 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8443962 | pubmed:articleTitle | Study of induction of activation of human peripheral blood mononuclear cells with a non-activating form of anti-CD3 MoAb in autoimmune thyroid disease (AITD). | lld:pubmed |
| pubmed-article:8443962 | pubmed:affiliation | Department of Medicine, Wellesley Hospital, University of Toronto, Ontario, Canada. | lld:pubmed |
| pubmed-article:8443962 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8443962 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
